

Jackson Tang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2993103/publications.pdf>

Version: 2024-02-01

22
papers

691
citations

840119

11
h-index

676716

22
g-index

22
all docs

22
docs citations

22
times ranked

956
citing authors

#	ARTICLE	IF	CITATIONS
1	Employees With Fibromyalgia: Medical Comorbidity, Healthcare Costs, and Work Loss. <i>Journal of Occupational and Environmental Medicine</i> , 2008, 50, 13-24.	0.9	149
2	Disease-Related and All-Cause Health Care Costs of Elderly Patients With Gout. <i>Journal of Managed Care Pharmacy</i> , 2008, 14, 164-175.	2.2	93
3	Economic burden of psoriasis compared to the general population and stratified by disease severity. <i>Current Medical Research and Opinion</i> , 2009, 25, 2429-2438.	0.9	86
4	Frequency, Risk, and Cost of Gout-related Episodes Among the Elderly: Does Serum Uric Acid Level Matter?. <i>Journal of Rheumatology</i> , 2009, 36, 1032-1040.	1.0	79
5	Direct and indirect costs among employees with diabetic retinopathy in the United States. <i>Current Medical Research and Opinion</i> , 2008, 24, 1549-1559.	0.9	57
6	Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn's Disease. <i>Pharmacoeconomics</i> , 2009, 27, 609-621.	1.7	40
7	Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy. <i>Current Medical Research and Opinion</i> , 2015, 31, 757-765.	0.9	39
8	Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis. <i>Current Medical Research and Opinion</i> , 2014, 30, 123-130.	0.9	31
9	Loss of Treatment Response to Infliximab Maintenance Therapy in Crohn's Disease: A Payor Perspective. <i>Value in Health</i> , 2008, 11, 820-829.	0.1	25
10	Determinants of Direct Cost Differences among US Employees with Major Depressive Disorders Using Antidepressants. <i>Pharmacoeconomics</i> , 2009, 27, 507-517.	1.7	25
11	Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment. <i>Current Medical Research and Opinion</i> , 2015, 31, 767-777.	0.9	13
12	Relationship between transfusion burden, healthcare resource utilization, and complications in patients with beta-thalassemia in Taiwan: A real-world analysis. <i>Transfusion</i> , 2021, 61, 2906-2917.	0.8	12
13	Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons. <i>Journal of Medical Economics</i> , 2010, 13, 314-323.	1.0	7
14	Gastrointestinal events and association with initiation of treatment for osteoporosis. <i>ClinicoEconomics and Outcomes Research</i> , 2015, 7, 603.	0.7	7
15	History of cardiovascular events and cardiovascular risk factors among patients initiating strontium ranelate for treatment of osteoporosis. <i>International Journal of Women's Health</i> , 2015, 7, 913.	1.1	6
16	Why physicians do not initiate dual therapy as recommended by AACE guidelines: A survey of clinicians in the United States. <i>Diabetes Research and Clinical Practice</i> , 2015, 108, 456-465.	1.1	5
17	Risk factors associated with treatment discontinuation and down-titration in type 2 diabetes patients treated with sulfonylureas. <i>Current Medical Research and Opinion</i> , 2016, 32, 1567-1575.	0.9	5
18	Association of gastrointestinal events with osteoporosis treatment initiation and treatment compliance in Germany: An observational study. <i>Bone Reports</i> , 2016, 5, 208-213.	0.2	5

#	ARTICLE	IF	CITATIONS
19	Antidepressant treatment patterns and costs among US employees. <i>Journal of Medical Economics</i> , 2009, 12, 36-45.	1.0	3
20	Impact of hypoglycemic events and HbA1c level on sulfonylurea discontinuation and down-titration. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 213-220.	0.7	2
21	Association between gastrointestinal events and osteoporosis treatment initiation in women diagnosed with osteoporosis in France: a retrospective analysis. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 195.	0.8	1
22	Costs associated with adverse events for systemic therapies in metastatic melanoma. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 867-879.	0.6	1